U.S. Kidney Care (USRC) will treat COVID-19 patients with single clone antibodies (Bamlanivimab) at dialysis clinics

American Kidney Care (USRC), a leading provider of dialysis services in the United States, which cares for more than 26,000 patients with kidney disease, announced that it will offer the monoclonal antibody therapy Bamlanivimab to patients with kidney disease recently diagnosed with COVID-19.
USRC obtained Bamlanivimab through operation Warp Speed and Project SPEED programs and will use the drug in dialysis clinics for patients with mild to moderate COVID-19.
. Mary Dittrich, chief medical officer of the USRC, said: "Our internal data are consistent with data from CMS, which show that patients with end-stage kidney disease have a very high rate of hospitalization after developing COVID-19.
in our clinics, monoclonal antibody therapy for patients with COVID-19 who need dialysis can reduce hospitalization and save lives."
Bamlanivimab, manufactured by Eli Lilly and distributed by Amerisource Bergen, has been granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 for non-hospitalized patients 12 years and older.
recently published in the New England Journal of Medicine, data showing that bamlanivimab blocks virus attachment and cell entry show a significant reduction in hospitalizations for high-risk patients treated with Bamlanivimab within the recommended time frame.
。